Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054873 | 1.00 | HCRTR2 (0.45) | HCRTR2ELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18569885 | 1.00 | HCRTR2 (0.45) | HCRTR2ELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18569448 | 0.91 | ELANE (0.50) | HCRTR2ELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16402963 | 0.91 | ELANE (0.50) | HCRTR2ELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7491781 | 0.88 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2HTR2C | |
| SCHEMBL116053 | 0.85 | ALDH1A1 (0.46) | HCRTR2 | |
| SCHEMBL3398953 | 0.85 | ALDH1A1 (0.46) | HCRTR2 | |
| SCHEMBL6941068 | 0.84 | AGTR2 (0.47) | NPC1RAB9ASMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL5765292 | 0.84 | AGTR2 (0.47) | NPC1RAB9ASMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL20446568 | 0.84 | AGTR2 (0.47) | NPC1RAB9ASMN1; SMN2TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004084-B1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-3004084-B1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9493472-B2 | Substituted benzoxazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9493472-B2 | Substituted benzoxazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-3004084-A1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195231-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | HCRTR2 3448/4885ELANE 447/4885NPC1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.